Electronic Drug Delivery Systems Market Size and Forecast
Electronic Drug Delivery Systems Market was valued at USD 7.57 Billion in 2019 and is projected to reach USD 14.51 Billion by 2027, growing at a CAGR of 8.5% from 2020 to 2027.
The Global Electronic Drug Delivery Systems Market report provides a holistic evaluation of the market for the forecast period. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market. These factors; the market dynamics involve the drivers, restraints, opportunities, and challenges through which the impact of these factors in the market is outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Electronic Drug Delivery Systems Market study provides an outlook on the development of the market in terms of revenue throughout the prognosis period.
Get | Download Sample Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=40792&utm_source=Free&utm_medium=004
Global Electronic Drug Delivery Systems Market Definition
Amongst the various drug delivery technologies, electronic drug delivery systems (EDDS) showcases a promising trend in the expansion of drug delivery systems, which are portable, interactive, wirelessly connected, and permits patient-administered therapy, which curbs the overall healthcare cost. The electronic drug delivery systems are used to offer sustained delivery, attainment of higher bioavailability, the improvement in patient outcomes. The insulin pump is frequently used EDDS and captures the highest market revenue of the global EDDS market.
In the infusion drug delivery system, the exact dosage measurement is a vital step while administering to the patients. The dosing motor consists of the three-phase BLDC (brushless DC) types with a few wattage power (e.g., using 12V). For flow sensing, a custom-sensor is used. The Bluetooth communication is enabled to provide an up-to-date GUI via smartphone. The end products may also require a continuous power supply (e.g., using Li-ion cells). This design uses an amalgamation of two Microcontroller Units (MCUs), which includes the RA6M3 for the motor regulator and sensor measurement, and the RX23W for Bluetooth Low Energy (BLE) 5 communication. The upgradation of patient compliance while using arranged medication is one of the driving forces in the development of EDDS. Furthermore, EDDS has shown the potential to provide targeted drug delivery to particular sites in the body. The utilization of radiofrequency waves to release encapsulated drug compounds is being considered as a minimally invasive approach.
The role of biologic drugs will improve market revenue. They improvise the standard of care across many diseases. The devices to address the biologic drug delivery bears a resemblance to the conventional capsules. The regular pills carry the miniature electronic device sensors. The size of the invention, which is directly linked to drug loading size, acts as an essential boundary condition towards programming an oral drug delivery device, and information gathered from clinical associates helps to set dimensional restrictions and drug load per ingested device. This is being done to overcome the challenges posed by the GI tract while the biologic drug is injected. The biologics will bring investment in the product portfolio of new drug delivery systems such as auto-injectors. The future of electronic drug delivery systems is the use of Microneedle (MNs) as an emerging drug delivery carrier to provide effective treatment in diabetic patients. It combines the use of diagnostic and therapeutic applications. The Microneedle can achieve drug delivery in a minimally invasive manner, which results in pain -free administration, ease to handle, providing a controlled release system.
Global Electronic Drug Delivery Systems Market Overview
The onset of target diseases is the critical factor causing a surge in market growth. Tuberculosis occurred in every part of the world, with 10 million new cases in 2017. According to the World Health Organization, around 219 million malaria cases were reported worldwide. In 2019, 463 million adults who were aged 20-79 years were living with diabetes. In 2045, the count will increase to 700 million. The favorable reimbursements being deployed in upcoming markets will bolster the market growth. The upcoming technological advancements in the electronic drug delivery systems will pave the way for profitable opportunities in the market revenue. The onset of Industry 4.0 and technology is renovating the landscape of drug delivery. By building digital technology into drug delivery devices, the issues of patient adherence can be solved. The 3M Intelligent Controller is an electronic inhaler that is constructed to diagnose patients who have asthma and chronic obstructive pulmonary disease (COPD). The sensor in the inhaler is programmed to detect whether the patient has inhaled for a longer duration to attain the full prescription of the drug. Although the product is not available for commercial sale, the inhaler can be connected to the smartphone. The systems will make the patient remind about the duration of the drug to be taken and providing instructions on how to use it. It will record the length of the dosage taken, and it will provide guidance, set a reminder, and improve the healthcare decisions made by the patient in the coming future. The t slim X2 Insulin Pump, by Tandem Diabetes Care, is the first FDA approved insulin pump proficient of remote feature updates. By using the personal computer or smartphone, the patients can keep their pump up to date with the latest technology during its contract period.
Another factor that will aid the electronic drug delivery systems gain traction in the design segment. The research scientists and engineers have started to work from the base level (understanding the patient’s health system). The goal is to understand the circumstances od the patient’s health and the challenges being faced. The major vendors launching new products is catalyzing the market growth. In January 2020, Medtronic showcased Effico, a cloud-based data management software integrated with the SynchroMed II intrathecal drug delivery system. The software enables clinicians to efficiently achieve their targeted drug delivery pump practices to cure patients with chronic pain, cancer pain, and severe spasticity. Other factors such as the increased awareness about the use of electronic drug delivery systems among the consumer base population, extensive disbursement by Research and Development towards the private industries will furnish the market growth.
However, there are certain restraints and challenges which are likely to deter market growth. The use of substitute drug delivery systems in place of electronic drug delivery systems are being adopted, due to the rapid onset, reliability, minimum occurrence of errors. Other factors are the lack of expertise to handle the systems, the improper calibration of the drug dispensing machines.
Global Electronic Drug Delivery Systems Market: Segmentation Analysis
The Global Electronic Drug Delivery Systems Market is segmented based on Product, Applications, and Geography.
Electronic Drug Delivery Systems Market by Product
Based on Product, the market is bifurcated electronic wearable infusion pumps, electronic autoinjectors, electronic injection pens, and electric inhalers. The electronic wearable infusion pumps are predicted to hold the largest market share. The factors can be attributed to the commercial production of the electronic infusion pumps to cure the patients who have diabetes.
Electronic Drug Delivery Systems Market by Applications
Based on Applications, the market is bifurcated into Diabetes, Multiple Sclerosis, Cardiovascular Diseases, Asthma, and Chronic Obstructive Pulmonary Disorder. The Diabetes segment is anticipated to hold the highest CAGR in the forecast period. The rise in patient population suffering from diabetes increased availability of insulin pumps, and injection pens by significant players are anticipated to attain the fastest growing market.
Electronic Drug Delivery Systems Market by Geography
On the basis of regional analysis, the Global Electronic Drug Delivery Systems Market is classified into North America, Europe, Asia Pacific, and Rest of the world. The largest share in the market will be dominated by North America. The increased incidence of target diseases, a rise in the patient population, favorable remuneration policies, and the launch of advanced electronic drug delivery systems by significant players are attributed to the increase in market revenue.
Global Electronic Drug Delivery Systems Market Competitive Landscape
The “Global Electronic Drug Delivery Systems Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Merck Group (Germany), Insulet Corporation (US), Bayer AG (Germany), Medtronic plc (Ireland), Novo Nordisk (Denmark), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), and Amgen (US). The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.